公司新闻
https://chimebiologics.com/wp-content/uploads/2024/05/3z-1.png
383
900
chi9iua
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
chi9iua2024-05-23 18:36:522025-06-12 14:00:34生物类似药中美欧法规速递
https://chimebiologics.com/wp-content/uploads/2024/04/Collaborative-whitepaper.jpg
383
900
chi9iua
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
chi9iua2024-04-19 17:46:332025-06-16 18:50:02白皮书 | 单克隆抗体类原研药和生物类似药的免疫原性对比
https://chimebiologics.com/wp-content/uploads/2024/03/9767d405-4a42-4920-bf40-d2de7d681a83.png
383
900
Qiqi Zhang
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
Qiqi Zhang2024-03-12 16:00:442025-06-12 14:07:59Domain Therapeutics 与鼎康生物宣布达成生产协议,推动新型抗CCR8 抗体用于癌症免疫疗法
https://chimebiologics.com/wp-content/uploads/2023/10/582af528-b2ba-4133-83c4-b8b4e8546a3f.jpg
383
900
Qiqi Zhang
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
Qiqi Zhang2023-09-28 13:18:512025-06-16 15:48:05鼎康生物与和其瑞医药达成战略合作,加速治疗子宫内膜异位症及雄激素脱发抗体创新药物上市进程
https://chimebiologics.com/wp-content/uploads/2023/09/头图1员工-1.png
383
900
Qiqi Zhang
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
Qiqi Zhang2023-09-20 09:50:222025-06-16 15:48:27鼎康生物与韩国Kings Pharm达成生物类似药项目合作,推进抗肿瘤生物类似药的全球临床供应和商业化生产
https://chimebiologics.com/wp-content/uploads/2023/09/企业微信截图_abfb6e3d-e04e-4de2-a943-01f4560984511.png
383
900
Qiqi Zhang
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
Qiqi Zhang2023-09-19 14:38:462025-06-16 15:48:57鼎康生物与韩国Panolos Bioscience签署全球项目合作协议,共同推进多特异性蛋白药物开发
https://chimebiologics.com/wp-content/uploads/2023/08/1.jpg
460
1080
Qiqi Zhang
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
Qiqi Zhang2023-08-17 13:42:132025-06-12 15:46:37鼎康生物再次入选“2023胡润全球未来独角兽”,企业成长性获市场长期认可
